Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck stock (NYSE: MRK ... compared to $25 billion in 2023. Secondly, the next best-selling product – Gardasil – faced headwinds in China, resulting in its sales falling in the recent quarters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback